CytoDyn Inc. (CYDY)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in CytoDyn Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

CytoDyn Inc. (CYDY) has returned -2.14% so far this year and 19.15% over the past 12 months. Over the last ten years, CYDY has returned -11.46% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Jul 16, 2007, CYDY's average daily return is +0.32%, while the average monthly return is +3.43%. At this rate, your investment would double in approximately 1.7 years.

Historically, 42% of months were positive and 58% were negative. The best month was Dec 2019 with a return of +257.1%, while the worst month was Nov 2007 at -66.7%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 8 months.

On a daily basis, CYDY closed higher 36% of trading days. The best single day was Aug 11, 2009 with a return of +142.9%, while the worst single day was Jun 25, 2008 at -66.7%.

CytoDyn Inc. has an annualized alpha of 123.05%, beta of 0.01, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since July 17, 2007.

• This stock participated in 122.32% of S&P 500 Index downside but only 68.34% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.01 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CYDY ranks 50 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for CytoDyn Inc. (CYDY) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the CytoDyn Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the CytoDyn Inc. was 98.76%, occurring on Dec 5, 2024. The portfolio has not yet recovered.

The current CytoDyn Inc. drawdown is 96.88%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of CytoDyn Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how CytoDyn Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.